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Background
Acute colonic pseudo-obstruction (ACPO) refers to dilatation of the colon and decreased 
bowel motility without evidence of mechanical obstruction. Neostigmine, an acetylcholi-
nesterase inhibitor, has been used in patients in whom supportive therapy failed to resolve 
ACPO. Here, we report the results of administering neostigmine to treat ACPO in children 
with hematologic malignancies.
Methods
Between September 2005 and December 2009, 10 patients (8 male and 2 female) were 
diagnosed with ACPO at the Department of Pediatrics, Catholic University of Korea. 
Diagnosis of ACPO was based on typical clinical features as well as colonic dilatation found 
on abdominal CT imaging. Neostigmine was administered subcutaneously at a dosage 
of 0.01 mg/kg/dose (maximum 0.5 mg) twice daily for a maximum of 5 total doses. ACPO 
was determined to be responsive to neostigmine if the patient showed both stool passage 
and improvement of clinical symptoms. 
Results
 The study group included 8 acute lymphoblastic leukemia patients, 1 patient with malig-
nant lymphoma, and 1 patient with juvenile myelomonocytic leukemia. The median age 
at ACPO diagnosis was 8.5 years (range, 3-14). Overall, 8 patients (80%) showed ther-
apeutic response to neostigmine at a median of 29 hours after the initial administration 
(range, 1-70). Two patients (20%) showed side effects of grade 2 or above, but none com-
plained of cardiovascular symptoms that required treatment. 
Conclusion
  In this study, ACPO was diagnosed most often in late-childhood ALL patients. 
Subcutaneous neostigmine can be used to effectively treat ACPO diagnosed in children 
with hematologic malignancies without major cardiovascular complications.
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INTRODUCTION
  Acute colonic pseudo-obstruction (ACPO), also known 
as Ogilvie’s syndrome, refers to massive colonic dilatation 
with combined symptoms and signs of colonic obstruction 
without overt mechanical blockage. Important predisposing 
factors for the development of ACPO include trauma, in-
fections, and cardiac disease as well as underlying medical 
illnesses such as cancer. If left untreated, ACPO may lead 
to intestinal perforation in 3-15% of cases, with an estimated 
mortality rate of 50% once spontaneous perforation occurs 
[1].
  Once ACPO is diagnosed, treatment options include con-
servative management or colonoscopic decompression if 
symptoms fail to show improvement with initial care. 
Neostigmine, an acetylcholinesterase inhibitor, has shown 
efficacy in the treatment of ACPO without exposing the 
patient to the rare but significant complication of colonic 
perforation that accompanies colonoscopy, and since the ini-
tial study of successful decompression of ACPO using neo-Korean J Hematol 2010;45:62-5.
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Table 1. Demographic characteristics of the study group (N=10).
N (%)
Gender 
Male 8 (80)
Female 2 (20)
Age at diagnosis of ACPO
Median (range) 8.5 (3-14)
≤5 years 3 (30)
5-10 years 5 (50)
＞10 years 2 (20)
Main diagnosis
ALL 8 (80)
DLBL 1 (10)
JMMoL 1 (10)
Abbreviations: ACPO, acute colonic pseudo-obstruction; ALL, acute
lymphoblastic leukemia; DLBL, diffuse large B-cell lymphoma;
JMMoL, juvenile myelomonocytic leukemia.
Table 2. Patient history at ACPO diagnosis (N=10).
N (%)
Most recent chemotherapy
Vincristine, daunorubicin, asparaginase, 
dexamethasone
5 (50)
Vincristine, cytarabine, dexamethasone 2 (20)
Vincristine, ifosfamide, methotrexate, 
cytarabine, etoposide, dexamethasone
1 (10)
Vincristine, daunorubicin, cytarabine, 
dexamethasone
1 (10)
Vincristine, cytarabine, etoposide 1 (10)
Neutropenia (≤1,000/mm
3)
Moderate 3 (30)
Severe 4 (40)
Antibiotic use
Yes 8 (80)
No 2 (20)
stigmine [2], several reports have reaffirmed the utility of 
neostigmine in treating this rare but potentially life-threat-
ening phenomenon [3, 4]. However, the effectiveness of 
neostigmine in treating ACPO diagnosed solely in a group 
of hematology patients has yet to be proven.
  Intestinal complications are frequently observed in cancer 
patients. Typhilitis, or inflammation of the cecum, is a necrot-
izing enterocolitis that occurs in neutropenic patients after 
chemotherapy. Chemotherapeutic agents as far ranging as 
vincristine and docetaxel have been implicated in the patho-
genesis of megacolon [5, 6].
  Here, we report our single-institution experience of ad-
ministrating neostigmine for the treatment of ACPO that 
was diagnosed in a series of pediatric patients with hemato-
logic malignancies.
MATERIALS AND METHODS
1. Study population
  The study group consisted of consecutive hematology pa-
tients diagnosed with ACPO between September 2005 (the 
time period when neostigmine was first administered for 
the treatment of ACPO) and December 2009 at the Depart-
ment of Pediatrics, Catholic University of Korea. Overall, 
10 patients were diagnosed with ACPO during this period 
and treated with neostigmine. The major characteristics of 
this group are outlined in Table 1. The median age at ACPO 
diagnosis was 8.5 years, and 7 patients (70%) were older 
than 5 years. Eight patients (80%) had been diagnosed with 
and treated for acute lymphoblastic leukemia (ALL), 6 of 
whom had been designated as high-risk or above.
2. Diagnosis of ACPO
  Since literature on the diagnosis of ACPO in the pediatric 
population is scarce, we implemented certain unique criteria 
for ACPO diagnosis as follows:
  1) Symptoms of bowel obstruction such as constipation, 
abdominal pain, nausea, and vomiting
  2 )  F i n d i n g s  o n  a b d o m i n a l  C T  i m a g i n g  c o n s i s t e n t  w i t h  
colonic dilatation without overt mechanical obstruction, that 
characterize ACPO, as confirmed by a pediatric radiologist.
3. Neostigmine administration
  The administration protocol was as follows:
  1) Neostigmine was given subcutaneously at a dosage of 
0.01 mg/kg/dose (maximum, 0.5 mg/dose) twice daily.
  2)  If no major side effects were noted with initial neo-
stigmine infusion, administration was continued until ther-
apeutic response, defined as stool passage and relief of me-
chanical obstruction symptoms, was observed. One addi-
tional neostigmine infusion was allowed after the patient 
showed treatment response in order to expedite full relief 
from ACPO. A maximum of 5 total doses of neostigmine 
were given. If a patient’s symptoms failed to show improve-
ment after the fifth neostigmine infusion, then the patient’s 
ACPO was deemed unresponsive to neostigmine and no fur-
ther infusion was attempted.
  3) With each administration of neostigmine, vital signs 
and ECG monitoring were undertaken in order to identify 
possible bradycardia, and atropine was prepared at the bed-
side. All major side effects were noted and graded according 
to NCI CTC version 2.0. With regard to abdominal pain, 
newly developed pain or definite aggravation of previous 
pain after neostigmine infusion was considered a major side 
effect.
RESULTS
1. Diagnosis of ACPO
  The median time from diagnosis of underlying malignancy 
to ACPO was 38.5 days (range, 21-121 days). The most com-
mon sign or symptom at diagnosis was abdominal pain (7/10, Korean J Hematol 2010;45:62-5.
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Table 3. Neostigmine administration and response (N=10).
N (%)
Number of doses administered
2 doses 5 (50)
3 doses 1 (10)
4 doses 1 (10)
5 doses 3 (30)
Overall response to neostigmine
Yes 8 (80)
No 2 (20)
Time to response (hours from initial infusion)
Median (range) 29 (1-70)
Fig. 1. An 11-year-old male patient 
diagnosed with Philadelphia chro-
mosome-positive ALL failed to pass 
stools for 157 hours before an ab-
dominal CT was undertaken. Initial 
imaging showed massive colonic 
dilatation and fecal impaction con-
sistent with ACPO, with the maxi-
mum diameter of the ascending 
colon measuring approximately 6.7 
cm (A). Four hours after imaging, 
the patient was started on subcu-
taneous neostigmine, which resulted
in stool passage 1 hour later. The 
patient received 1 more infusion for
rapid amelioration of symptoms. 
Follow-up imaging taken 7 days 
later showed improvement in both 
colonic dilatation and fecal loading 
with a decrease in the maximum 
diameter of the ascending colon to 
4.8 cm (B).
70%), which was followed by fever (3/10, 30%), vomiting 
(2/10, 20%), and loose stools (1/10, 10%). The median max-
imum diameter of the ascending colon on CT imaging at 
diagnosis was 4.9 cm (range, 4.2-6.9 cm).
2. Patient history at ACPO diagnosis
  The chemotherapeutic regimens infused immediately pri-
or to the diagnosis of ACPO are listed in Table 2. All 10 
patients had previously received chemotherapy including 
vincristine, with a median of 8.5 days since the last infusion 
of vincristine (range, 4-10 days). Remission induction chemo-
therapy for ALL was the most common regimen given prior 
to ACPO diagnosis (5 patients, 50%), and it was followed 
by consolidation chemotherapy for ALL (3 patients, 30%). 
The majority of patients were neutropenic (7 patients, 70%: 
3 patients with moderate neutropenia and 4 patients with 
severe neutropenia) and receiving broad-spectrum anti-
biotics at the time of ACPO diagnosis. Only 1 patient each 
had been receiving narcotic analgesics for relief of abdominal 
pain and had a potassium level ＜3.0 mEq/L at the time 
of ACPO diagnosis (data not shown).
3. Neostigmine administration and response
  Details of neostigmine administration and responses to 
treatment are outlined in Table 3. A median of 18.5 hours 
(range, 4-31 hours) passed between diagnosis of ACPO to 
initial neostigmine infusion, during which time the patients 
received conservative management, such as nasogastric suc-
tion, laxatives, and enemas. Half of the patients showed 
improvement in clinical symptoms after 1 day of neostigmine 
infusion (2 doses). The overall response rate to neostigmine 
was 80% (8/10); a typical case of ACPO improvement result-
ing from neostigmine is shown in Fig. 1. The clinical course 
of the 2 patients whose conditions failed to respond to neo-
stigmine was as follows: one patient, who was diagnosed 
with Philadelphia chromosome-positive ALL, experienced 
ACPO during induction chemotherapy. The patient con-
tinued to complain of constipation and abdominal pain de-
spite neostigmine infusion, and further infusion was stopped 
after the fourth dose. This patient passed stools and experi-
enced symptom improvement 105 hours after the last infu-
sion. The second patient, who was also diagnosed with ACPO 
during remission induction chemotherapy for ALL, received 
the maximum number of doses (5 doses) without symptom 
relief but passed stools 77 hours after the last infusion. None 
of the patients, including the 2 who did not respond to 
neostigmine, showed recurrence of ACPO during the fol-
low-up period.
4. Side effects of neostigmine infusion
  One patient experienced diplopia (grade 2), and another 
experienced aggravated abdominal pain (grade 2) after neo-
stigmine infusion. Neither of these patients required specific 
medication for these symptoms. None of the patients had 
cardiovascular complications such as symptomatic brady-
cardia or syncope after neostigmine treatment.Korean J Hematol 2010;45:62-5.
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DISCUSSION
  ACPO can be associated with a wide range of medical 
conditions and, as such, studies on the use of neostigmine 
for the treatment of this condition have largely been based 
on a heterogeneous patient population. Furthermore, liter-
ature on ACPO and its treatment in patients with hemato-
logic diseases or children with cancer is scarce, with limited 
case reports on successful use of neostigmine for decom-
pression of ACPO [7-9].
  Our study is unique in that ACPO was diagnosed and 
treated in a homogeneous group of children with underlying 
hematologic malignancies who were accrued over a period 
o f  m o r e  t h a n  4  y e a r s .  I n  t h is patient group, ACPO was 
most commonly diagnosed in school-aged children with ALL, 
with the median age at diagnosis being 8.5 years. ACPO 
tended to be observed soon after initiation of diagnosis and 
treatment for hematologic malignancy, lessening the possi-
bility that this significant complication resulted from gradual 
and prolonged accumulation of chemotherapy-related 
toxicity. Importantly, most of the patients were neutropenic 
and were receiving antibiotic therapy at the time of ACPO 
diagnosis, indicating the potential role of post-chemotherapy 
neutropenia as a triggering factor for this gastrointestinal 
disorder, as is the case for typhilitis. A case report on the 
diagnosis and treatment of ACPO in an adult with acute 
myeloid leukemia also emphasizes neutropenia as an im-
portant factor in the development of ACPO and underscores 
the utility of both cholinergic agents and granulocyte-colony 
stimulating factor for its resolution [7]. All patients had been 
previously treated with a chemotherapeutic regimen that 
included vincristine, and an average of 1 week had passed 
from the most recent vincristine injection to ACPO diagnosis. 
However, the ACPO diagnosed in our patients should be 
differentiated from the constipation that may develop as 
an adverse effect of vincristine therapy. First, neurotoxicity 
from vincristine is dose-related and cumulative [10] while, 
as noted above, these study patients tended to be diagnosed 
with ACPO early on in their primary disease course without 
experiencing symptom recurrence despite full chemotherapy 
treatment. Second, other neurologic symptoms that charac-
terize vincristine neurotoxicity, such as motor and sensory 
symptoms and autonomic neuropathy in the form of urinary 
retention [11], were not evident in our patients. Instead 
of being the sole causative agent of these gastrointestinal 
symptoms, recent treatment with vincristine may, like neu-
tropenia, act as a significant predisposing factor for the devel-
opment of ACPO.
  Although the number of patients in the study group is 
small, the overall response of ACPO to neostigmine was 
impressive: 80% (8/10) of patients showed clinical improve-
ment after neostigmine administration, with most of the 
responses coming after just 1 day (2 dosages) of treatment. 
Furthermore, in contrast to previous studies that utilized 
intravenous injection of neostigmine, we treated the study 
patients with neostigmine administered subcutaneously in 
an attempt to minimize the potential for significant car-
diovascular complications while maintaining a therapeutic 
cholinergic effect. Possibly due to this different route of 
drug administration, none of the patients experienced major 
side effects that required intervention. However, the median 
time to response after initial drug administration was also 
significantly longer (29 hours) than has been reported by 
that employed intravenous injection of neostigmine. Since 
the clinical course of this study group was not compared 
with that of a control group of ACPO patients who did 
not receive neostigmine, the potential benefit of our medical 
intervention cannot be fully measured. However, consider-
ing that the 2 patients who did not respond to neostigmine 
started to show symptom improvement 3-4 days after the 
last infusion, one may speculate that the course of ACPO 
in children with hematologic malignancies is protracted, 
possibly lending itself to other major complications such 
as intestinal perforation and neutropenic shock.
  In conclusion, although the number of patients in the 
study group is limited, our results indicate that subcutaneous 
neostigmine is both effective and safe for the treatment of 
ACPO diagnosed in children with hematologic malignancies.
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